chrX-78273682-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_006639.4(CYSLTR1):c.65G>A(p.Arg22His) variant causes a missense change. The variant allele was found at a frequency of 0.000048 in 1,208,546 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 23 hemizygotes in GnomAD. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000027 ( 0 hom., 2 hem., cov: 22)
Exomes 𝑓: 0.000050 ( 0 hom. 21 hem. )
Consequence
CYSLTR1
NM_006639.4 missense
NM_006639.4 missense
Scores
2
9
6
Clinical Significance
Conservation
PhyloP100: 5.88
Genes affected
CYSLTR1 (HGNC:17451): (cysteinyl leukotriene receptor 1) This gene encodes a member of the G-protein coupled receptor 1 family. The encoded protein is a receptor for cysteinyl leukotrienes, and is involved in mediating bronchoconstriction via activation of a phosphatidylinositol-calcium second messenger system. Activation of the encoded receptor results in contraction and proliferation of bronchial smooth muscle cells, eosinophil migration, and damage to the mucus layer in the lung. Upregulation of this gene is associated with asthma and dysregulation may also be implicated in cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High Hemizygotes in GnomAd4 at 2 gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CYSLTR1 | NM_006639.4 | c.65G>A | p.Arg22His | missense_variant | 3/3 | ENST00000373304.4 | |
CYSLTR1 | NM_001282186.2 | c.65G>A | p.Arg22His | missense_variant | 2/2 | ||
CYSLTR1 | NM_001282187.2 | c.65G>A | p.Arg22His | missense_variant | 4/4 | ||
CYSLTR1 | NM_001282188.2 | c.65G>A | p.Arg22His | missense_variant | 4/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CYSLTR1 | ENST00000373304.4 | c.65G>A | p.Arg22His | missense_variant | 3/3 | 1 | NM_006639.4 | P1 | |
CYSLTR1 | ENST00000614798.1 | c.65G>A | p.Arg22His | missense_variant | 2/2 | 1 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000268 AC: 3AN: 111860Hom.: 0 Cov.: 22 AF XY: 0.0000587 AC XY: 2AN XY: 34058
GnomAD3 genomes
AF:
AC:
3
AN:
111860
Hom.:
Cov.:
22
AF XY:
AC XY:
2
AN XY:
34058
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000603 AC: 11AN: 182292Hom.: 0 AF XY: 0.0000448 AC XY: 3AN XY: 66954
GnomAD3 exomes
AF:
AC:
11
AN:
182292
Hom.:
AF XY:
AC XY:
3
AN XY:
66954
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000502 AC: 55AN: 1096686Hom.: 0 Cov.: 32 AF XY: 0.0000580 AC XY: 21AN XY: 362116
GnomAD4 exome
AF:
AC:
55
AN:
1096686
Hom.:
Cov.:
32
AF XY:
AC XY:
21
AN XY:
362116
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000268 AC: 3AN: 111860Hom.: 0 Cov.: 22 AF XY: 0.0000587 AC XY: 2AN XY: 34058
GnomAD4 genome
AF:
AC:
3
AN:
111860
Hom.:
Cov.:
22
AF XY:
AC XY:
2
AN XY:
34058
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
8
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 26, 2022 | The c.65G>A (p.R22H) alteration is located in exon 3 (coding exon 1) of the CYSLTR1 gene. This alteration results from a G to A substitution at nucleotide position 65, causing the arginine (R) at amino acid position 22 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Uncertain
D;D
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D
M_CAP
Benign
T
MetaRNN
Uncertain
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;.
REVEL
Uncertain
Sift
Uncertain
D;.
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MutPred
Gain of loop (P = 0.1069);Gain of loop (P = 0.1069);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at